PANDA Therapeutics receives CHF 40,000 from Venture Kick to advance next-generation Alzheimer’s therapy toward clinic
27.03.2026
Panda Therapeutics receives CHF 40,000 from Venture Kick to advance its next-generation therapy for Alzheimer’s disease. By developing a pan-amyloid bio-conjugate that targets multiple pathological mechanisms with a single molecule, the startup aims to improve the effectiveness of disease-modifying treatments and address unmet needs in Alzheimer’s care.
 CEO Hui Zhang
|
 |
What was the first real signal that your solution worked outside the lab or pitch deck, and what did that moment change for you?
The first real signal came when both academia and industry increasingly emphasized co-pathology in Alzheimer’s disease, which is exactly what our solution targets.
That alignment validated the significance of our approach. It was the moment we fully committed to developing this solution and working toward improving the lives of Alzheimer’s patients.
Can you briefly describe your project and where it stood when you entered Venture Kick?
Our project focuses on developing a next-generation therapy for Alzheimer’s disease. Building on the recently approved disease-modifying treatments, we are designing a pan-amyloid bio-conjugate that can target multiple pathological mechanisms with a single molecule.
When we entered Venture Kick, we were in the final prototyping phase and preparing to start lead optimization.
How has the direction of your product/service/product strategy changed since working with the Venture Kick Team?
Venture Kick helped us significantly on the business side. Coming from a scientific background, we gained a new perspective on how to position and communicate our project.
It helped us translate complex science into a clearer story that resonates with non-scientific audiences, especially investors.
How will the Stage 2 funding help you advance your project concretely?
Stage 2 funding will help us accelerate proof-of-concept validation of our prototype.
It will also support securing our intellectual property in key markets, including China, the U.S., and Japan.
The first real signal came when both academia and industry increasingly emphasized co-pathology in Alzheimer’s disease, which is exactly what our solution targets.
That alignment validated the significance of our approach. It was the moment we fully committed to developing this solution and working toward improving the lives of Alzheimer’s patients.
Can you briefly describe your project and where it stood when you entered Venture Kick?
Our project focuses on developing a next-generation therapy for Alzheimer’s disease. Building on the recently approved disease-modifying treatments, we are designing a pan-amyloid bio-conjugate that can target multiple pathological mechanisms with a single molecule.
When we entered Venture Kick, we were in the final prototyping phase and preparing to start lead optimization.
How has the direction of your product/service/product strategy changed since working with the Venture Kick Team?
Venture Kick helped us significantly on the business side. Coming from a scientific background, we gained a new perspective on how to position and communicate our project.
It helped us translate complex science into a clearer story that resonates with non-scientific audiences, especially investors.
How will the Stage 2 funding help you advance your project concretely?
Stage 2 funding will help us accelerate proof-of-concept validation of our prototype.
It will also support securing our intellectual property in key markets, including China, the U.S., and Japan.